Microbio received the approval from TFDA to initiate the MB-6 Phase III clinical trial. Microbio spokesperson responded that MB-6 is the third self-developed drug candidate that has obtained approval from TFDA to initiate human clinical trials. MB-6 is an adjuvant to colorectal cancer therapy. The previous two candidates were Chemo Young (Approved in 2011) and Herbiron which is currently under NDA review and expecting approval in the second half of 2013.